Tectonic Therapeutic, Inc. Price & Performance (TECX)

Tectonic Therapeutic has completed its reverse merger with Avrobio, marking a significant shift in the biotech landscape. The combined entity, retaining the Tectonic name, is set to operate from Massachusetts and expects to have $165 million in cash, supporting operations and pipeline advancement through mid-2027.12

Following its merger with Avrobio, Tectonic Therapeutic is drawing bullish analyst sentiment, with price targets suggesting over 270% potential upside. The company, now trading under the ticker TECX, is backed by a consensus buy rating and aims to leverage its advanced GPCR-targeting technology for future growth.34

Avrobio investors will hold about 22% of the merged company with Tectonic Therapeutic, while Tectonic shareholders control 40%. The leadership team from Tectonic will guide the new entity, which is expected to accelerate drug development efforts in cardiovascular and rare diseases.25